IFM Investors Pty Ltd Buys Shares of 9,133 Hologic, Inc. (HOLX)

IFM Investors Pty Ltd bought a new position in Hologic, Inc. (NASDAQ:HOLX) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 9,133 shares of the medical equipment provider’s stock, valued at approximately $335,000.

A number of other hedge funds have also added to or reduced their stakes in the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in Hologic by 0.4% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 20,803 shares of the medical equipment provider’s stock worth $944,000 after purchasing an additional 85 shares during the period. Symphony Asset Management LLC increased its stake in Hologic by 0.4% in the second quarter. Symphony Asset Management LLC now owns 28,005 shares of the medical equipment provider’s stock worth $1,271,000 after purchasing an additional 108 shares during the period. Cutter & CO Brokerage Inc. increased its stake in Hologic by 1.7% in the second quarter. Cutter & CO Brokerage Inc. now owns 11,530 shares of the medical equipment provider’s stock worth $523,000 after purchasing an additional 190 shares during the period. Hall Laurie J Trustee increased its stake in Hologic by 10.2% in the second quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock worth $110,000 after purchasing an additional 225 shares during the period. Finally, Pacer Advisors Inc. increased its stake in Hologic by 3.4% in the second quarter. Pacer Advisors Inc. now owns 8,413 shares of the medical equipment provider’s stock worth $382,000 after purchasing an additional 279 shares during the period. Institutional investors and hedge funds own 98.08% of the company’s stock.

In related news, VP Karleen Marie Oberton sold 1,023 shares of the firm’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $39.84, for a total transaction of $40,756.32. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Lawrence M. Levy sold 9,596 shares of the firm’s stock in a transaction dated Tuesday, October 10th. The shares were sold at an average price of $36.81, for a total value of $353,228.76. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 28,833 shares of company stock worth $1,107,270. 0.79% of the stock is owned by corporate insiders.

A number of research firms have recently issued reports on HOLX. Needham & Company LLC reissued a “buy” rating and set a $48.00 price target (up previously from $46.00) on shares of Hologic in a research report on Tuesday, December 5th. Piper Jaffray Companies reissued a “buy” rating and set a $48.00 price target on shares of Hologic in a research report on Thursday, November 9th. Jefferies Group reissued a “buy” rating and set a $44.00 price target (down previously from $49.00) on shares of Hologic in a research report on Tuesday, October 10th. Stifel Nicolaus reissued a “buy” rating and set a $45.00 price target (down previously from $48.00) on shares of Hologic in a research report on Monday, October 9th. Finally, Goldman Sachs Group raised Hologic from a “buy” rating to a “conviction-buy” rating and increased their price target for the stock from $45.00 to $50.00 in a research report on Friday, December 8th. One analyst has rated the stock with a sell rating, five have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $47.86.

Shares of Hologic, Inc. (NASDAQ HOLX) opened at $43.53 on Monday. Hologic, Inc. has a 12-month low of $35.76 and a 12-month high of $46.80. The firm has a market capitalization of $12,000.52, a PE ratio of 21.55, a P/E/G ratio of 2.10 and a beta of 0.95. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.61 and a current ratio of 0.79.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.01. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The company had revenue of $802.90 million for the quarter, compared to the consensus estimate of $792.54 million. During the same quarter last year, the company earned $0.52 earnings per share. The firm’s revenue for the quarter was up 10.5% compared to the same quarter last year. equities analysts expect that Hologic, Inc. will post 2.12 EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.com-unik.info/2017/12/18/ifm-investors-pty-ltd-buys-shares-of-9133-hologic-inc-holx.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

What are top analysts saying about Hologic? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Hologic and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit